Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zebrowski, B. K.
Right arrow Articles by Ellis, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zebrowski, B. K.
Right arrow Articles by Ellis, L. M.
Clinical Cancer Research Vol. 5, 3364-3368, November 1999
© 1999 American Association for Cancer Research

Advances in Brief

Vascular Endothelial Growth Factor Levels and Induction of Permeability in Malignant Pleural Effusions1

Brian K. Zebrowski, Seiji Yano, Wenbiao Liu, Raymond M. Shaheen, Daniel J. Hicklin, Joe B. Putnam, Jr. and Lee M. Ellis2

Departments of Surgical Oncology [B. K. Z., R. M. S., L. M. E.], Cancer Biology [S. Y., W. L., L. M. E.], and Thoracic Surgery [J. B. P.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Imclone Systems, Inc. [D. J. H.], New York, New York 10014

Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis and vascular permeability. We hypothesized that malignant pleural effusions may contain high levels of VEGF protein as well as other cytokines implicated in these processes. Pleural effusions cytologically proven to be malignant were collected from 39 patients with various types of cancer, and VEGF, interleukin-8, and angiogenin levels in the effusions were determined by immunoassay. Negative controls were nonmalignant ascites and serum samples from healthy individuals. VEGF levels were significantly higher than those of control samples in pleural effusions secondary to breast, mesothelioma, and non-small cell lung cancer and when all malignant pleural effusion samples were pooled. Neither interleukin-8 nor angiogenin levels were elevated in malignant pleural effusions relative to the control samples. Vascular permeability, which was measured by using the Miles assay in nude mice, was increased proportionately with VEGF levels in the malignant pleural effusions; this increase in permeability induced by injection of recombinant VEGF or the malignant effusions was reduced by pretreating the mice with a VEGF receptor antibody.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
G. T. Stathopoulos, C. Moschos, H. Loutrari, A. Kollintza, I. Psallidas, S. Karabela, S. Magkouta, Z. Zhou, S. A. Papiris, C. Roussos, et al.
Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion
Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 50 - 59.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. T. Stathopoulos, A. Kollintza, C. Moschos, I. Psallidas, T. P. Sherrill, E. N. Pitsinos, S. Vassiliou, M. Karatza, S. A. Papiris, D. Graf, et al.
Tumor Necrosis Factor-{alpha} Promotes Malignant Pleural Effusion
Cancer Res., October 15, 2007; 67(20): 9825 - 9834.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli, P. Maione, A. Rossi, and F. De Marinis
The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments
Oncologist, October 1, 2007; 12(10): 1183 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. S. Tsao, D. He, B. Saigal, S. Liu, J. J. Lee, S. Bakkannagari, N. G. Ordonez, W. K. Hong, I. Wistuba, and F. M. Johnson
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
Mol. Cancer Ther., July 1, 2007; 6(7): 1962 - 1972.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hossein Pourgholami, Z. Yan Cai, Y. Lu, L. Wang, and D. Lawson Morris
Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice.
Clin. Cancer Res., March 15, 2006; 12(6): 1928 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Amino, Y. Ideyama, M. Yamano, S. Kuromitsu, K. Tajinda, K. Samizu, H. Hisamichi, A. Matsuhisa, K. Shirasuna, M. Kudoh, et al.
YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors
Clin. Cancer Res., March 1, 2006; 12(5): 1630 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Davidson, V. Espina, S. M. Steinberg, V. A. Florenes, L. A. Liotta, G. B. Kristensen, C. G. Trope, A. Berner, and E. C. Kohn
Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling
Clin. Cancer Res., February 1, 2006; 12(3): 791 - 799.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. Demirag, E. Unsal, A. Yilmaz, and A. Caglar
Prognostic Significance of Vascular Endothelial Growth Factor, Tumor Necrosis, and Mitotic Activity Index in Malignant Pleural Mesothelioma
Chest, November 1, 2005; 128(5): 3382 - 3387.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Hicklin and L. M. Ellis
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. S. Wang, J. Teruya-Feldstein, Y. Wu, Z. Zhu, D. J. Hicklin, and M. A. S. Moore
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo
Blood, November 1, 2004; 104(9): 2893 - 2902.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Sarkar, D. Chakroborty, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu
Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells
Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1554 - H1560.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Yamada, K. Sato, M. Komachi, E. Malchinkhuu, M. Tobo, T. Kimura, A. Kuwabara, Y. Yanagita, T. Ikeya, Y. Tanahashi, et al.
Lysophosphatidic Acid (LPA) in Malignant Ascites Stimulates Motility of Human Pancreatic Cancer Cells through LPA1
J. Biol. Chem., February 20, 2004; 279(8): 6595 - 6605.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S K Mohanty and P Dey
Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review
Postgrad. Med. J., October 1, 2003; 79(936): 569 - 574.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
O. Stoeltzing, W. Liu, N. Reinmuth, A. Parikh, S. A. Ahmad, Y. D. Jung, F. Fan, and L. M. Ellis
Angiogenesis and Antiangiogenic Therapy of Colon Cancer Liver Metastasis
Ann. Surg. Oncol., August 1, 2003; 10(7): 722 - 733.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. van Hensbergen, H. J. Broxterman, R. Hanemaaijer, A. S. Jorna, N. A. van Lent, H. M. W. Verheul, H. M. Pinedo, and K. Hoekman
Soluble Aminopeptidase N/CD13 in Malignant and Nonmalignant Effusions and Intratumoral Fluid
Clin. Cancer Res., December 1, 2002; 8(12): 3747 - 3754.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. F. Dvorak
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. Hata, K. Tanaka, T. Imaizumi, T. Ohara, T. Ohba, T. Shinada, and T. Takano
Clinical Significance of Pleural Effusion in Acute Aortic Dissection
Chest, March 1, 2002; 121(3): 825 - 830.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. ROMANO, A. CATALANO, M. NUTINI, E. D'URBANO, C. CRESCENZI, J. CLARIA, R. LIBNER, G. DAVI, and A. PROCOPIO
5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor
FASEB J, November 1, 2001; 15(13): 2326 - 2336.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Catalano, M. Romano, I. Robuffo, L. Strizzi, and A. Procopio
Methionine Aminopeptidase-2 Regulates Human Mesothelioma Cell Survival : Role of Bcl-2 Expression and Telomerase Activity
Am. J. Pathol., August 1, 2001; 159(2): 721 - 731.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
L. J. Metheny-Barlow, B. Flynn, H. E. van Gijssel, A. Marrogi, and B. I. Gerwin
Paradoxical Effects of Platelet-Derived Growth Factor-A Overexpression in Malignant Mesothelioma . Antiproliferative Effects In Vitro and Tumorigenic Stimulation In Vivo
Am. J. Respir. Cell Mol. Biol., June 1, 2001; 24(6): 694 - 702.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.